banner
News center
Classy appearance

Safety Considerations for Challenges When Using Smart Infusion Pumps

Dec 11, 2023

Problem: Organizations must customize their smart infusion pump drug libraries and tailor each to their needs. However, drug library customization requires dedicated resources to review the literature, compare the parameters in the drug libraries with actual clinical practice, and determine safeguards for each infusion in the drug library. Organizations must also continually ensure that the library content is up to date and that the most recent version has been downloaded and is active on all of their smart pumps. Unfortunately, ISMP has received reports related to safety risk and limitations that healthcare practitioners face when trying to optimize drug libraries and implement important safeguards to prevent catastrophic programming errors.

Several medications, including opioids, benzodiazepines, and anticoagulants, do not have a universal maximum dose published in the official prescribing information; instead, they have widely variable doses based on the medication's indication, patient-specific parameters, tolerability, or clinical response. Without a maximum dose built into the smart pump library, a programming error, including programming doses or rates 10-fold or greater than intended (e.g., entering 200 mg instead of 20 mg, 19 units/hour instead of 1.9 units/hour) could lead to significant patient harm. For example, if a heparin protocol does not include a maximum dose, the team that builds the smart pump drug library will need to achieve consensus to set it. While the smart pump team may try to capture most dose scenarios, they may not know where to draw the line for patients who receive doses that are higher or lower than typical doses for clinically appropriate reasons. Yet, if a smart pump issues a hard stop for a dose outside the limits but the dose is still clinically appropriate for the patient, the practitioner will likely need to revert to a risk-prone process of manually programming the heparin infusion without engaging the dose error-reduction system (DERS).

Medications with wide dosing parameters or variable rates of infusion cause added challenges when building dose range limits in drug libraries. The smart pump team may have difficulty building effective safeguards while accommodating the variable doses and infusion rates for medications titrated to patients’ clinical responses, used for different indications, or based on the patients’ tolerability. The following are examples that highlight these challenges.

Clinical response. Titratable medications, such as vasopressors, require prescribers to order an initial rate of infusion, titration parameters including the frequency of titration, the maximum dose or rate of infusion, and an objective clinical measure to guide changes. If the smart pump team setting the minimum and maximum dose limits does not consider the full range of the titration across all patients, the result is possible nuisance alerts or unnecessary hard stops for the practitioner programming the pump.

Indication. For mechanically ventilated patients in the intensive care unit (ICU), the typical dose of a ketamine continuous infusion for analgesia, sedation, agitation, or chronic pain is much lower than the dose of this medication infusion used for refractory status epilepticus based on a goal of electrographic suppression. If only one option exists in the smart pump library for ketamine, which has up to a 10-fold difference in safe dosage ranges based on its indication, a practitioner who makes a programming error may not receive an alert.

Tolerability. Prescribers may incrementally increase the rate of certain chemotherapy and immunosuppressants based on the patient's tolerability, rather than titrating to a clinical endpoint. For example, when used for certain indications, riTUXimab has an initial infusion rate with incremental increases every 30 minutes unless hypersensitivity or an infusion-related reaction occurs.

For each of these situations, practitioners who make programming errors will either not receive clinically important alerts if the dose limits are too wide, or will receive nuisance alerts or hard stops if the dose limits are too narrow. Nuisance alerts that happen regularly contribute to alert fatigue and workarounds that can result in administering the medication infusion without engaging the DERS.

Patients may require a continuous opioid infusion or patient-controlled analgesia (PCA) for a variety of indications, including pain management or end-of-life care. There are large differences in opioid doses, rates, and concentrations used to treat opioid-naïve patients compared to opioid-tolerant patients. Like the scenarios described above, if there is only one option for each opioid medication infusion, nuisance alerts may fire for opioid-tolerant patients if the dose range limits are too narrow, or clinically important alerts may not fire for opioid-naïve patients if the upper limits are too high.

When patients receive a continuous infusion, practitioners may be required to directly administer a bolus dose of the same medication from the continuous infusion. This is only safe if the smart pump has a bolus dose feature that administers the correct dose and volume for the bolus dose at the correct rate, and then automatically resumes the continuous infusion at the earlier rate. Without prebuilt bolus options, an unsafe workaround occurs when a practitioner simply increases the rate of infusion to administer the bolus dose, and then must remember to manually return the infusion to the prior rate settings after the bolus dose has been administered. A second issue seen with bolus doses is when the volume of the bolus consumes a large amount of the infusion provided, which may cause confusion and delays. Consider these error-prone scenarios:

A prescriber ordered a bolus dose of 3,200 units of heparin for a 40 kg child receiving a heparin infusion via a syringe pump. To administer the bolus from the 100 units/mL infusion, it would require administration of 32 mL, more than half of the current syringe volume. The nurse assumed the pharmacy would dispense a more concentrated heparin syringe for the bolus dose. However, the pharmacy did not dispense a separate bolus dose because the heparin order set in the electronic health record (EHR) did not specify how to administer it, and pharmacy staff did not realize the bolus dose would consume more than half of the volume in the syringe already infusing, resulting in a delay in care.

A prescriber ordered an opioid bolus dose for a patient receiving an opioid infusion, but the bolus exceeded the maximum hard limit in the drug library. As a result, the practitioner bypassed the bolus dose feature and administered the bolus by increasing the rate of the continuous opioid infusion. Fortunately, this at-risk behavior did not adversely affect the patient, and the practitioner remembered to decrease the opioid infusion rate after the bolus dose had been administered. Unfortunately, this sent the wrong message to the practitioner, that taking this risk was an acceptable practice; sooner or later, someone will forget to adjust the rate.

Some organizations lack the resources and/or expertise for ongoing maintenance, updating, and testing of the software and drug library for all smart infusion pumps. Smart infusion pumps are limited by the software version and drug library installed on the devices, making it imperative to regularly update the drug library in every device. For example, after changing a standard concentration of a medication infusion due to a drug shortage or formulary change, if organizations do not update the libraries on all the pumps, the practitioner may select an incorrect concentration resulting in a programming error. Or, if the practitioner cannot find the new concentration, it may delay patient care. We shared similar concerns with concentration errors in our June 16, 2022, feature article on safely transitioning to new drug concentrations.

Safe Practice Recommendations: Consider the following recommendations to address the described smart infusion pump challenges:

Establish and approve dose limits. Establish and/or evaluate minimum and maximum dose limits for each medication infusion and bolus dose that requires infusion via a smart infusion pump. Determine if the dose limits should be weight-based or non-weight based, aligning the dose limits with organizational protocols, dosing references, literature, and clinical practice. Engage end users (e.g., nurses, anesthesia providers) when deciding if medication infusions and bolus doses need to have more than one drug library entry due to wide dosing parameters or variable rates. For example, consider providing two library options for opioid infusions and bolus doses based on the patient's opioid status (naïve versus tolerant). Also consider the full range of titration when setting dose limits for titratable infusions. Smart infusion pump dosing limits should not cause nuisance alerts or prevent the programming of incremental doses.

Reach a consensus on each medication infusion and bolus dose limits and determine soft and hard limits. This will require a search of the literature and analysis of organization-specific prescribing and pump data that reflect current clinical usage, doses, and practices. Be aware that continuous infusion units are generally dosed per hour while boluses may be dosed per minute. While reviewing past pump data, examine outliers to determine if they were planned or may have been errors. For example, if an order calls for a dose of up to 100 mcg/kg/hour but the patient is titrated up to 270 mcg/kg/hour, be suspicious of an error. Once the drug library parameters have been determined, require approval by an interdisciplinary committee before updating or creating the drug library. Also determine and communicate a process for practitioners to request changes to the set limits.

Use the EHR to drive safe practice. Because smart pump dose alerts or hard stops detect and/or prevent catastrophic programming errors and serve only as a final layer of protection against administering overdoses, establish dose range checking in the EHR to notify prescribers and pharmacists up front if it is likely that a medication infusion dose has been prescribed outside of a safe dose range. Also, configure the EHR to notify prescribers and pharmacists that a medication infusion requires a change in concentration if the dose falls outside of the capability of the organizational pumps (e.g., less than 0.1 mL/hour for a 50 mL syringe). Require all titratable medication orders to include the medication name; route; initial or starting rate; incremental units the rate can be increased or decreased; frequency of dose titrations; maximum rate of infusion; and an objective clinical measure to guide changes. Ideally, match medication names in the smart pump with the names in the medication administration record (MAR) and EHR.

Create drug libraries. Once the dose limits and hard stops have been established and approved, set soft dosing limits in the smart pump drug library that reflect the maximum expected dose and rate prescribed as well as a buffer for patients who may require more or less than the typical default doses and rates. Set hard dosing limits as a forcing function to prevent catastrophic errors, while considering patients who may clinically require atypical doses, to prevent end users from needing to program the infusion without engaging the DERS. Incorporate a process to double check the drug library build prior to releasing it onto the pumps.

Limit multiple indication-based options. If different indication-based library entries are needed for certain medication infusions, determine if the infusion is only used for a single indication in a specific location, and limit the drug library for that location to only one option, when possible. Otherwise, let end users know about the infusions that have multiple indication-based options. If possible, clearly include the indication in the drug name selection on the pump.

Test the drug library. Test the drug library to ensure that soft and hard stops will capture a variety of prescribing and programming errors. Specifically test hard stops to ensure they will capture and prevent 10-fold under- and overdose errors. For medication infusions with two options in the drug library based on the indication, make it obvious to the end users which option to select, or this could lead to unintended downstream effects or programming errors. For example, if oxytocin has a peripartum option with a lower dose range limit for induction and a postpartum option with a higher dose range limit for bleeding, have end users review the naming convention used for each indication of oxytocin in the drug library as well as the associated workflow to ensure it is intuitive to select and switch between the two options.

Differentiate opioid status. In alignment with the ISMP Targeted Medication Safety Best Practices for Hospitals, verify and document a patient's opioid status (naïve versus tolerant) before prescribing and dispensing continuous infusions of opioids. Default order entry systems to the lowest initial opioid starting dose. Review the literature and analyze organization-specific prescribing and pump data to build order sets with dosing guidance that differentiate opioid-naïve versus opioid-tolerant patients. During opioid prescribing, automatically link products with the corresponding concentration that pharmacists will dispense. Design the drug library options and limits to reflect the order sets and to be intuitive for end users. Consider whether your patient population warrants having a separate palliative or end-of-life care drug library. Additionally, instead of relying on end users to select the correct opioid concentration from a menu of multiple options, consider establishing entries defined by a dose threshold (e.g., morphine less than or equal to 5 mg/hour or greater than 5 mg/hour), with specific concentrations restricted to opioid-tolerant patients.

Limit bolus doses from a continuous infusion. Only allow practitioners to administer a bolus dose from a continuous infusion if your infusion pump has a bolus feature that automatically resumes the continuous infusion rate once that bolus dose has been administered, and if your drug library includes bolus dose range limits. For large volume bolus doses or when several medications are running through the same line, consider dispensing and administering the bolus dose separately.

Communicate how end users should administer bolus doses. On the EHR/MAR, clearly show the route and rate of administration of the bolus, and whether the pharmacy will dispense a separate bolus (or verify a bolus dose from an automated dispensing cabinet [ADC]), or the practitioner should administer the bolus from the continuous infusion via a bolus infusion feature. If the pharmacy dispenses a separate bolus dose (or verifies removal from an ADC), specify on the EHR/MAR whether it will be in a syringe or a bag/bottle, which might require a different infusion pump or channel and a separate administration set. If dispensing a bolus dose in a syringe for pediatric patients, electronically determine the syringe size based on the volume of the dose and the required rate of infusion.

Track all smart pumps. Provide the necessary resources to track all smart infusion pumps, regardless of the location in the organization, to ensure timely software and drug library updates as well as ongoing biomedical inspections and maintenance. Some infusion pump vendors provide a central server to help track infusion pumps by serial number; others use radio frequency identification (RFID) tags on the devices to track the approximate physical location of infusion pumps, both of which can be used to help find missing infusion pumps that need to be inspected or updated.

Update drug libraries. Update drug libraries at least quarterly and establish criteria for off-schedule updates needed to address drug shortages, new drugs added to the formulary, new drug protocols, or concentration changes. Implement a standard process for communicating drug library content changes to end users, including the updated drug library go-live date, the modified information, and directions on how to ensure the infusion pump has the newest library version. Include the organization's name as part of the drug library name, so users can quickly identify whether an infusion pump is from an outside organization. Consider using the current month and year (e.g., September 2022) as a naming convention for library updates to inform the user that they are using the most current drug library. While we recommend the purchase or lease of smart infusion pumps capable of wireless drug library updates, some pumps require a physical connection to a computer to update the library. Whether you have wireless capability or a manual library update process, develop a method to track the update status of each pump and investigate pumps that have not been updated.

Review pump data. Have the smart infusion pump team regularly monitor drug library usage and alerts, including overridden soft alerts, and adjust the dose limits as needed based on current practice and the literature. If a patient's dose falls outside a defined hard limit and the practitioner must administer the medication outside of the DERS, require an independent double check. Consider using a checklist/form to standardize and document the process, ensuring all necessary steps are followed. Use this checklist/form to communicate the outliers to the smart pump programming team and the pharmacy. Also if there are any safety reports related to the use of the smart pump, notify the smart pump team for follow-up. Continuous monitoring and reevaluation of the data is imperative to determine warranted adjustments to the drug library and possibly hospital dosing protocols.

Plan for interoperability. Implement bi-directional (i.e., auto-programming and auto-documentation) smart infusion pump interoperability with the EHR to reduce the risk of infusion pump programming errors. Employ the above recommendations to prepare for a smooth interoperability implementation. To learn more about infusion pump and EHR interoperability, see our Guidelines for Optimizing Safe Implementation and Use of Smart Infusion Pumps.

Work with pump vendors. Collaborate with your smart pump vendor and provide feedback for consideration for future upgrades. For example, share how character limits in the drug library might affect the display of the medication name, potentially increasing the opportunity for error as well as increasing the difficulty in finding a medication in the library. To cite another example, displaying options in a logical order for pediatric patients might require manipulating the weight or adding extra spaces or characters so doses for 1 kg patients appear before doses for 10 to 20 kg patients. Smart pump vendors must consider human factors to enhance the physical design of the pump and drug library, and to improve the programming experience for end users.

Suggested citation:

Institute for Safe Medication Practices (ISMP). Safety considerations for challenges when using smart infusion pumps. ISMP Medication Safety Alert! Acute Care. 2022;27(21):1-5.

You must be logged in to view and download this document.

Forgot Password?

Register Now

Problem: Clinical response. Indication. Tolerability. TUX Safe Practice Recommendations: Establish and approve dose limits. Use the EHR to drive safe practice. Create drug libraries. Limit multiple indication-based options. Test the drug library. Differentiate opioid status. Targeted Medication Safety Best Practices for Hospitals Limit bolus doses from a continuous infusion. and Communicate how end users should administer bolus doses. Track all smart pumps. Update drug libraries. Review pump data. Plan for interoperability. Guidelines for Optimizing Safe Implementation and Use of Smart Infusion Pumps Work with pump vendors.